At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 555 enrolled
Drug / intervention
IDP-118 Lotiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating IDP-118 Lotion for Plaque Psoriasis. Completed, enrolled 555 participants across 46 sites.
Detailed Summary
The objective of this study is to evaluate the long-term safety of IDP-118 lotion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
CollaboratorsDow Pharmaceutical Sciences
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartAug 2015
Primary CompletionJan 2017
Study CompletionApr 2017
TodayJul 2026
First PostedJun 3, 2015
Enrollment StartAug 11, 2015
Primary CompletionJan 31, 2017
Study CompletionApr 24, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.1 years ago
Interventions
IDP-118 Lotiondrug
IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.